Enalare Therapeutics Invited to Present at BARDA Industry Day 2021
PRINCETON, N.J., November 2, 2021 (Newswire.com) - Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has been invited to present at the BARDA Industry Day being held virtually Nov. 3-4, 2021. The Biomedical Advanced Research and Development Authority (BARDA) is a component of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services and is focused on the development of medical countermeasures to protect Americans and respond to 21st-century health security threats. Daniel Motto, Enalare's Chief Operating Officer, will highlight how the successful partnership with BARDA is accelerating the development of Enalare's lead drug candidate ENA-001 as a potential treatment for respiratory depression in both mass casualty situations and the drug overdose epidemic.
BARDA Industry Day has grown into a premier annual health security event featuring keynote presentations by industry and government partners exploring cutting-edge innovation of medical countermeasures. Last year's event attracted more than 1,300 attendees.
"We are thrilled to be presenting at this prestigious and important industry event," stated Herm Cukier, Enalare's President and CEO. "We greatly value BARDA's partnership in the development of our one-of-a-kind new chemical entity and look forward to furthering the relationship as the clinical program advances."
About Enalare Therapeutics Inc.
Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening acute respiratory and critical care conditions, including drug overdose, post-surgery respiratory depression, and apnea of prematurity. The Company is planning to initiate further clinical studies with its lead compound ENA-001 in the near term.
This project has been supported in whole or in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Contract No. 75A50121C00044.
Enalare Investor Relations
Source: Enalare Therapeutics